FAQ on Soligenix Inc.'s Phase 3 Progress for HyBryte(TM) in CTCL Treatment

What is HyBryte(TM) and what is its target condition?

HyBryte(TM) is a topical therapy activated by visible light, targeting early-stage mycosis fungoides, which accounts for nearly 90% of cutaneous T-cell lymphoma (CTCL) cases.

What were the key findings from the interim results of the Phase 3 trial?

Among the first eight patients who completed 18 weeks of treatment, 75% demonstrated a greater than 50% reduction in disease severity.

When are the top-line results from the Phase 3 trial expected?

Soligenix anticipates top-line results from the phase 3 trial in the second half of 2026.

Who is leading the investigator-initiated study at the University of Pennsylvania?

The study is being conducted under the leadership of Dr. Ellen Kim at the University of Pennsylvania.

What is the significance of the Phase 3 progress for HyBryte(TM)?

The progress signifies a potential transformation in the treatment landscape for CTCL, offering a new therapeutic option for a rare and challenging condition.

How does HyBryte(TM) work?

HyBryte(TM) is applied directly to cancerous lesions on the skin and is activated by visible light, targeting the affected areas without systemic exposure.

Where can I find more information about Soligenix and its developments?

The latest news and updates relating to Soligenix (SNGX) are available in the company’s newsroom at https://ibn.fm/SNGX.

What is Soligenix’s focus as a biopharmaceutical company?

Soligenix is dedicated to developing and commercializing treatments for rare diseases and unmet medical needs, with HyBryte(TM) being its lead asset for CTCL.